Moderna(MRNA.US)涨超7% 两款新mRNA疫苗数据积极

Core Viewpoint - Moderna's stock price increased by over 7% to $27.85 following the presentation of new data on its mRNA vaccine pipeline at the IDWeek 2025 conference [1] Group 1: Vaccine Pipeline - Moderna showcased clinical results for its seasonal flu vaccine mRNA-1010 and the combination vaccine mRNA-1018 [1] - Both vaccines demonstrated the ability to elicit rapid and robust immune responses in adult subjects [1] - No significant safety issues were observed in the clinical trials for these vaccines [1]